Equities

AstraZeneca PLC

AZN:LSE

AstraZeneca PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)14,104.00
  • Today's Change124.00 / 0.89%
  • Shares traded3.06m
  • 1 Year change19.67%
  • Beta0.8573
Data delayed at least 20 minutes, as of Feb 06 2026 16:33 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 05-Feb-26
Select bar for recommendation details.
Recommendations05-Feb-26
Buy8
Outperform14
Hold3
Sell1
Strong Sell0

Share price forecast

The 23 analysts offering 12 month price targets for AstraZeneca plc have a median target of 15,399.32, with a high estimate of 18,280.26 and a low estimate of 6,390.67. The median estimate represents a 9.18% increase from the last price of 14,104.00.
High29.6%18,280.26
Med9.2%15,399.32
Low-54.7%6,390.67

Dividends

In 2024, AstraZeneca PLC reported a dividend of 3.07 USD, which represents a 5.97% increase over last year. The 22 analysts covering the company expect dividends of 3.24 USD for the upcoming fiscal year, an increase of 5.41%.
Div growth (TTM)5.97%
More ▼

Earnings history & estimates

On Nov 06, 2025, AstraZeneca plc reported 3rd quarter 2025 earnings of 2.38 per share. This result was in line with the consensus of the 13 analysts following the company and exceeded last year's 3rd quarter results by 14.42%.
The next earnings announcement is expected on Feb 10, 2026.
Average growth rate+4.11%
AstraZeneca plc reported annual 2024 earnings of 8.21 per share on Feb 06, 2025.
Average growth rate+19.90%
More ▼

Revenue history & estimates

AstraZeneca PLC had 3rd quarter 2025 revenues of 15.19bn. This bettered the 14.79bn consensus of the 13 analysts covering the company. This was 19.81% above the prior year's 3rd quarter results.
Average growth rate+3.12%
AstraZeneca PLC had revenues for the full year 2024 of 54.07bn. This was 18.03% above the prior year's results.
Average growth rate+20.11%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.